Therefore, it remains to be seen whether the desired price reduction can be achieved or not." Currently, two innovators are ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Novo Nordisk’s Wegovy has so far not been approved in India, and while rival drugmaker Eli Lilly was green-lighted for its ...

Novo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...

Novo Nordisk, the maker of Ozempic, Rybelsus and Wegovy, said in a statement to CBS News: "It's important that patients are aware that Novo Nordisk is the only company in the U.S. with FDA-approved ...

In the study, 33.4% of patients taking Wegovy were admitted, compared to about 37% in the placebo cohort. Use of the weight loss drug was also linked to shorter hospital stays. Eli Lilly and Novo ...

Nvidia topping Apple as the most valuable company in the world and joining the Dow Jones Industrial Average. Why Novo Nordisk and Eli Lilly are giving totally different reads on the markets for GLP-1 ...

Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

不过，Novo Nordisk开发副总裁Martin Holst Lange向分析师表示，他“有信心”更大规模的试验会证明CagriSema能帮助用户减重多达25%。Lange指出，公司基于先前试验的数据得出了这一预测。 Novo Nordisk表示，根据此前的试验，这款新药的安全性和耐受性预计与当前市面上的GLP-1药物相似。